Skip to main content
. 2016 Dec 27;1(3):260–264. doi: 10.1182/bloodadvances.2016000042

Table 1.

Expression of antigens in B-cell lineage ALL for potential antibody therapy

Surface antigen ALL subtype Expression (%) MoAb
CD20 Mature
B-cell precursor
86-100
30-40
Rituximab, ofatumumab, obinituzumab
CD19 Mature
B-cell precursor
95-<100
95-<100
Blinatumomab
CD22 Mature
B-cell precursor
∼100
93-98
Inotuzumab ozogamicin, epratuzumab, moxetumomab pasudotox

Adapted from Jabbour et al.2